Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

Chengzu Long, Leonela Amoasii, Alex A. Mireault, John R. McAnally, Hui Li, Efrain Sanchez-Ortiz, Samadrita Bhattacharyya, John M. Shelton, Rhonda Bassel-Duby, Eric N. Olson

Research output: Contribution to journalArticle

400 Citations (Scopus)

Abstract

CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene.To correctDMDby skippingmutant dystrophin exons in postnatalmuscle tissue in vivo,we used adeno-associated virus-9 (AAV9) to deliver gene-editing components to postnatal mdx mice, a model of DMD. Different modes of AAV9 delivery were systematically tested, including intraperitoneal at postnatal day 1 (P1), intramuscular at P12, and retro-orbital at P18. Each of thesemethods restored dystrophin protein expression in cardiac and skeletal muscle to varying degrees, and expression increased from 3 to 12 weeks after injection. Postnatal gene editing also enhanced skeletal muscle function, as measured by grip strength tests 4 weeks after injection.This method provides a potentialmeans of correctingmutations responsible for DMD and other monogenic disorders after birth.

Original languageEnglish (US)
Pages (from-to)400-403
Number of pages4
JournalScience
Volume351
Issue number6271
DOIs
StatePublished - Jan 22 2016

Fingerprint

Dystrophin
Duchenne Muscular Dystrophy
Muscular Dystrophies
Dependovirus
Skeletal Muscle
Clustered Regularly Interspaced Short Palindromic Repeats
Inbred mdx Mouse
Gene Components
Inborn Genetic Diseases
Injections
Hand Strength
Exons
Myocardium
Parturition
Mutation
Genes
Gene Editing
Proteins

ASJC Scopus subject areas

  • General

Cite this

Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., ... Olson, E. N. (2016). Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, 351(6271), 400-403. https://doi.org/10.1126/science.aad5725

Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. / Long, Chengzu; Amoasii, Leonela; Mireault, Alex A.; McAnally, John R.; Li, Hui; Sanchez-Ortiz, Efrain; Bhattacharyya, Samadrita; Shelton, John M.; Bassel-Duby, Rhonda; Olson, Eric N.

In: Science, Vol. 351, No. 6271, 22.01.2016, p. 400-403.

Research output: Contribution to journalArticle

Long, C, Amoasii, L, Mireault, AA, McAnally, JR, Li, H, Sanchez-Ortiz, E, Bhattacharyya, S, Shelton, JM, Bassel-Duby, R & Olson, EN 2016, 'Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy', Science, vol. 351, no. 6271, pp. 400-403. https://doi.org/10.1126/science.aad5725
Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016 Jan 22;351(6271):400-403. https://doi.org/10.1126/science.aad5725
Long, Chengzu ; Amoasii, Leonela ; Mireault, Alex A. ; McAnally, John R. ; Li, Hui ; Sanchez-Ortiz, Efrain ; Bhattacharyya, Samadrita ; Shelton, John M. ; Bassel-Duby, Rhonda ; Olson, Eric N. / Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. In: Science. 2016 ; Vol. 351, No. 6271. pp. 400-403.
@article{bcd23cde1aea4fb7b9d2eed569264b97,
title = "Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy",
abstract = "CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene.To correctDMDby skippingmutant dystrophin exons in postnatalmuscle tissue in vivo,we used adeno-associated virus-9 (AAV9) to deliver gene-editing components to postnatal mdx mice, a model of DMD. Different modes of AAV9 delivery were systematically tested, including intraperitoneal at postnatal day 1 (P1), intramuscular at P12, and retro-orbital at P18. Each of thesemethods restored dystrophin protein expression in cardiac and skeletal muscle to varying degrees, and expression increased from 3 to 12 weeks after injection. Postnatal gene editing also enhanced skeletal muscle function, as measured by grip strength tests 4 weeks after injection.This method provides a potentialmeans of correctingmutations responsible for DMD and other monogenic disorders after birth.",
author = "Chengzu Long and Leonela Amoasii and Mireault, {Alex A.} and McAnally, {John R.} and Hui Li and Efrain Sanchez-Ortiz and Samadrita Bhattacharyya and Shelton, {John M.} and Rhonda Bassel-Duby and Olson, {Eric N.}",
year = "2016",
month = "1",
day = "22",
doi = "10.1126/science.aad5725",
language = "English (US)",
volume = "351",
pages = "400--403",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6271",

}

TY - JOUR

T1 - Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

AU - Long, Chengzu

AU - Amoasii, Leonela

AU - Mireault, Alex A.

AU - McAnally, John R.

AU - Li, Hui

AU - Sanchez-Ortiz, Efrain

AU - Bhattacharyya, Samadrita

AU - Shelton, John M.

AU - Bassel-Duby, Rhonda

AU - Olson, Eric N.

PY - 2016/1/22

Y1 - 2016/1/22

N2 - CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene.To correctDMDby skippingmutant dystrophin exons in postnatalmuscle tissue in vivo,we used adeno-associated virus-9 (AAV9) to deliver gene-editing components to postnatal mdx mice, a model of DMD. Different modes of AAV9 delivery were systematically tested, including intraperitoneal at postnatal day 1 (P1), intramuscular at P12, and retro-orbital at P18. Each of thesemethods restored dystrophin protein expression in cardiac and skeletal muscle to varying degrees, and expression increased from 3 to 12 weeks after injection. Postnatal gene editing also enhanced skeletal muscle function, as measured by grip strength tests 4 weeks after injection.This method provides a potentialmeans of correctingmutations responsible for DMD and other monogenic disorders after birth.

AB - CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene.To correctDMDby skippingmutant dystrophin exons in postnatalmuscle tissue in vivo,we used adeno-associated virus-9 (AAV9) to deliver gene-editing components to postnatal mdx mice, a model of DMD. Different modes of AAV9 delivery were systematically tested, including intraperitoneal at postnatal day 1 (P1), intramuscular at P12, and retro-orbital at P18. Each of thesemethods restored dystrophin protein expression in cardiac and skeletal muscle to varying degrees, and expression increased from 3 to 12 weeks after injection. Postnatal gene editing also enhanced skeletal muscle function, as measured by grip strength tests 4 weeks after injection.This method provides a potentialmeans of correctingmutations responsible for DMD and other monogenic disorders after birth.

UR - http://www.scopus.com/inward/record.url?scp=84961291537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961291537&partnerID=8YFLogxK

U2 - 10.1126/science.aad5725

DO - 10.1126/science.aad5725

M3 - Article

VL - 351

SP - 400

EP - 403

JO - Science

JF - Science

SN - 0036-8075

IS - 6271

ER -